Long‐term survival and conditional survival of cancer patients in Japan using population‐based cancer registry data

Abstract

Although we usually report 5-year cancer survival using population-based cancer registry data, nowadays many cancer patients survive longer and need to be followed-up for more than 5 years. Long-term cancer survival figures are scarce in Japan. Here we report 10-year cancer survival and conditional survival using an established statistical approach. We received data on 1 387 489 cancer cases from six prefectural population-based cancer registries in Japan, diagnosed between 1993 and 2009 and followed-up for at least 5 years. We estimated the 10-year relative survival of patients who were followed-up between 2002 and 2006 using period analysis. Using this 10-year survival, we also calculated the conditional 5-year survival for cancer survivors who lived for some years after diagnosis. We reported 10-year survival and conditional survival of 23 types of cancer for 15–99-year-old patients and four types of cancer for children (0–14 years old) and adolescent and young adults (15–29 years old) patients by sex. Variation in 10-year cancer survival by site was wide, from 5% for pancreatic cancer to 95% for female thyroid cancer. Approximately 70–80% of children and adolescent and young adult cancer patients survived for more than 10 years. Conditional 5-year survival for most cancer sites increased according to years, whereas those for liver cancer and multiple myeloma did not increase. We reported 10-year cancer survival and conditional survival using population-based cancer registries in Japan. It is important for patients and clinicians to report these relevant figures using population-based data.

4-Methylthio-3-butenyl isothiocyanate (raphasatin) exerts chemopreventive effects against esophageal carcinogenesis in rats

“…In addition, it is one of the most lethal malignancies, with a 5-year survival rate of only 17% in the USA from 1996 to 2004 2 , 3 . In Japan, the 10-year relative survival rate of men with esophageal cancer was reported to be 24.0%; this was lower than those of other digestive tract cancers (gastric cancer, 61.3%; colon cancer, 68.9%) from 2002 to 2006 4 . Therefore, effective chemopreventive approaches against this disease are urgently required.…”

Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population‐based cancer registry data in Japan from 1993 to 2006

“…Conditional 5‐year survival for x ‐year survival is calculated as follows: divide the ( x + 5)‐year cumulative survival rate by the x ‐year cumulative survival, or calculate ( x + 5)‐year cumulative survival, limited to the x ‐year survivors. These methods are described in detail elsewhere …”

Impact of sex difference on survival of bladder cancer: A population‐based registry data in Japan

“…In addition, racial disparity in bladder cancer mortality has also been reported . The survival data of a wide variety of cancers in Japan was previously reported, including 23 types of adult cancer and four types of children, adolescent and young adult cancer using a large‐scale cancer registry database, and there was a sex difference in the survival of bladder cancer . However, no detailed analysis on the sex difference was carried out.…”